Which one can be taken every other day for prevention?

Nurtec: its label sets 75 mg every other day for the preventive treatment of episodic migraine. Ubrelvy's label states it is not indicated for prevention.

Can a second dose be taken in one day?

With Ubrelvy, yes: the label allows a second dose at least 2 hours after the first, up to 200 mg in 24 hours. With Nurtec, no: the maximum dose in 24 hours is one 75 mg tablet.

Are Nurtec and Ubrelvy triptans?

No. Both are CGRP receptor antagonists - gepants. Triptans are serotonin receptor agonists with a different mechanism and a much longer cardiovascular contraindication list in their labels.

MigraineTwo labels compared

Nurtec vs Ubrelvy

Nurtec and Ubrelvy are the two gepant tablets for treating a migraine attack, and the question that separates them is written into their labels: Nurtec is also approved for the preventive treatment of episodic migraine, while the Ubrelvy label states outright that it is not indicated for prevention. This page reads both documents side by side.

Nurtec ODT

Ingredient: Rimegepant
Approved for: Acute treatment of migraine, and prevention of episodic migrainecovers migraine
Supply: Prescription
Boxed warning: None
Pharmacy cost: $128.75 per tablet, capsule or pen, brandwhat pharmacies pay to buy it, not the price at the counter

Pfizer Laboratories Div Pfizer Inc. Label version 32, effective 4 June 2026.

Ubrelvy

Ingredient: Ubrogepant
Approved for: Acute treatment of migrainecovers migraine
Supply: Prescription
Boxed warning: None
Pharmacy cost: $109.17 per tablet, capsule or pen, brandwhat pharmacies pay to buy it, not the price at the counter

Allergan, Inc.. Label version 27, effective 5 June 2025.

01From the FDA label

Side by side, straight from the labels

Generated from the two source labels, not typed out by hand, so it cannot drift from what the regulator approved. Rows where both labels say exactly the same thing are marked.

Label section	Nurtec ODTRimegepant	UbrelvyUbrogepant
Active ingredient	Nurtec ODTRimegepantCGRP receptor antagonist (gepant)	UbrelvyUbrogepantCGRP receptor antagonist (gepant)
Approved for	Nurtec ODTAcute treatment of migraine, and prevention of episodic migraine	UbrelvyAcute treatment of migraine
Supplysame in both	Nurtec ODTPrescription	UbrelvyPrescription
What pharmacies payAcquisition cost, not retail	Nurtec ODT$128.75 per tablet, capsule or pen, brand	Ubrelvy$109.17 per tablet, capsule or pen, brand
Boxed warningsame in both	Nurtec ODTNone	UbrelvyNone
What the FDA approved it for	Nurtec ODT acute treatment of migraine with or without aura in adults preventive treatment of episodic migraine in adults Acute Treatment of Migraine NURTEC ODT is indicated for the acute treatment of migraine with or without aura in adults. Preventive Treatment of Episodic Migraine NURTEC ODT is indicated for the preventive treatment of episodic migraine in adults.	Ubrelvy Limitations of Use UBRELVY is not indicated for the preventive treatment of migraine. UBRELVY is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults.
Forms and strengths	Nurtec ODT Orally disintegrating tablets: white to off-white, circular, and debossed with the symbol, each containing 75 mg of rimegepant. NURTEC ODT orally disintegrating tablets: 75 mg	Ubrelvy UBRELVY 100 mg is supplied as white to off-white, capsule-shaped, biconvex tablets debossed with "U100" on one side. Tablets: 50 mg and 100 mg
How the label says it is taken	Nurtec ODT Recommended dosage for acute treatment of migraine: 75 mg taken orally, as needed. The safety of using more than 18 doses in a 30-day period has not been established. Recommended dosage for preventive treatment of episodic migraine: 75 mg taken orally every other day. The maximum dose in a 24-hour period is 75 mg. NURTEC ODT can be taken with or without food. Recommended Dosing for Acute Treatment of Migraine The recommended dose of NURTEC ODT is 75 mg taken orally, as needed. The maximum dose in a 24-hour period is 75 mg. The safety of using more than 18 doses in a 30-day period has not been established. NURTEC ODT can be taken with or without food.	Ubrelvy The recommended dose is 50 mg or 100 mg taken orally, as needed. If needed, a second dose may be administered at least 2 hours after the initial dose. The maximum dose in a 24-hour period is 200 mg. Severe Hepatic or Severe Renal Impairment: Recommended dose is 50 mg; if needed, a second 50 mg dose may be taken at least 2 hours after the initial dose.
Most common adverse reactions	Nurtec ODT most common adverse reaction in Study 1 was nausea (2% in patients who received NURTEC ODT compared to 0.4% of patients who received placebo). most common adverse reactions (occurring in at least 2% of rimegepant-treated patients and at a frequency of at least 1% higher than placebo) in Study 2 were nausea (2.7% in patients who received rimegepant compared with 0.8% of patients who received placebo) and abdominal pain/dyspepsia (2.4% in patients who received rimegepant compared with 0.8% of patients who received placebo).	Ubrelvy most common adverse reactions (at least 2% and greater than placebo) were nausea and somnolence. most common adverse reaction resulting in discontinuation in the long-term safety study was nausea.
Warnings and precautions	Nurtec ODT Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue NURTEC ODT and initiate appropriate therapy. Severe hypersensitivity reactions have included anaphylaxis, dyspnea, and rash, and can occur days after administration. Hypertension: New-onset or worsening of pre-existing hypertension may occur. Raynaud's Phenomenon: New-onset or worsening of pre-existing Raynaud's phenomenon may occur. Hypersensitivity Reactions Serious hypersensitivity reactions, including anaphylaxis, dyspnea, and rash, have occurred in patients treated with NURTEC ODT. Hypersensitivity reactions can occur days after administration, and delayed serious hypersensitivity has occurred.	Ubrelvy Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue UBRELVY and initiate appropriate therapy. Severe hypersensitivity reactions have included anaphylaxis and dyspnea. These reactions can occur within minutes, hours, or days after administration. Hypertension: New-onset or worsening of pre-existing hypertension may occur. Raynaud's phenomenon: New-onset or worsening of pre-existing Raynaud's phenomenon may occur. 5.1 Hypersensitivity Reactions Hypersensitivity reactions, including anaphylaxis, dyspnea, facial or throat edema, rash, urticaria, and pruritus, have been reported with use of UBRELVY. Hypersensitivity reactions can occur minutes, hours, or days after administration. Most reactions occurred within hours after dosing and were not serious, and some reactions led to discontinuation.
Contraindications	Nurtec ODT NURTEC ODT is contraindicated in patients with a history of hypersensitivity reaction to rimegepant, NURTEC ODT, or any of its components. Reactions have included anaphylaxis and delayed serious hypersensitivity.	Ubrelvy UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. Reactions have included anaphylaxis, dyspnea, and facial or throat edema Concomitant use with strong CYP3A4 inhibitors. History of serious hypersensitivity to ubrogepant or any component of UBRELVY.
Drug interactions	Nurtec ODT Strong CYP3A4 Inhibitors: Avoid concomitant administration. Moderate CYP3A4 Inhibitors: Avoid another dose within 48 hours when administered with a moderate CYP3A4 inhibitor. Strong and Moderate CYP3A Inducers: Avoid concomitant administration. Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. CYP3A4 Inhibitors Concomitant administration of NURTEC ODT with strong inhibitors of CYP3A4 results in a significant increase in rimegepant exposure. Avoid concomitant administration of NURTEC ODT with strong inhibitors of CYP3A4.	Ubrelvy Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. For additional dose modifications for moderate or weak CYP3A4 inhibitors and inducers or BCRP and/or P-gp only inhibitors, refer to section 2.2.
Label version	Nurtec ODT4 June 2026	Ubrelvy5 June 2025

02Written by us

Same class, one indication apart

Both labels cover the acute treatment of migraine with or without aura in adults, and both describe a CGRP receptor antagonist. Nurtec's label carries a second indication - preventive treatment of episodic migraine - with its own schedule of 75 mg every other day. Ubrelvy's label draws the line explicitly: not indicated for the preventive treatment of migraine.

03Written by us

Dosing runs on different rhythms

Nurtec is one 75 mg orally disintegrating tablet as needed, with a maximum of 75 mg in 24 hours and a note that the safety of more than 18 doses in 30 days has not been established. Ubrelvy is 50 mg or 100 mg as needed, with an optional second dose at least 2 hours later and a maximum of 200 mg in 24 hours.

04Written by us

Contraindications: hypersensitivity on one side, interactions on the other

Nurtec's label lists one contraindication, hypersensitivity to the product. Ubrelvy's adds a pharmacological one: concomitant use with strong CYP3A4 inhibitors. Neither carries the cardiovascular contraindication list of the triptans, and neither label has a boxed warning.

05Written by us

What this page does not tell you

It does not say which gepant works better: the two were approved on separate trial programs and their labels do not compare them. Choosing between them, or between this class and any other, is a prescriber's decision.

06Written by us

Common questions

Which one can be taken every other day for prevention?: Nurtec: its label sets 75 mg every other day for the preventive treatment of episodic migraine. Ubrelvy's label states it is not indicated for prevention.
Can a second dose be taken in one day?: With Ubrelvy, yes: the label allows a second dose at least 2 hours after the first, up to 200 mg in 24 hours. With Nurtec, no: the maximum dose in 24 hours is one 75 mg tablet.
Are Nurtec and Ubrelvy triptans?: No. Both are CGRP receptor antagonists - gepants. Triptans are serotonin receptor agonists with a different mechanism and a much longer cardiovascular contraindication list in their labels.

Sources

Every fact above comes from one of these documents. The date is the effective date of the label version this page was built from.

FDA prescribing information for Nurtec ODT
Pfizer Laboratories Div Pfizer Inc. Label version 32, effective 4 June 2026.
Full label on DailyMed Approval record NDA212728
FDA prescribing information for Ubrelvy
Allergan, Inc.. Label version 27, effective 5 June 2025.
Full label on DailyMed Approval record NDA211765

Each stripe is one section of the label, each division in a stripe one entry in that section.

Other comparisons in this category

Page last updated 29 August 2026

Compiled by the HealthyStudy editorial team from FDA source documents. No medical reviewer is credited on this page, because none reviewed it.